检索结果-南通市图书馆

World Journal of gastroenterology 2005年第34期11卷 5377-5380页

作者： Ping Fang Lei Dong Wei-Jin Zhang Jin-Yan Luo Department of internal medicine Second Hospital of Xi'an Jiaotong University Xi'an 710004 Shaanxi Province China Division of Cardiovascular Physiology and Pharmacology Medical School of Xi'an Jiaotong University Xi'an 710061 Shaanxi Province China

AIM： To investigate the effects of entero-hepatic bile add circulation on the inter-digestive migrating myoelectrical complex （MMC） in rats. METHODS： Thirty-two rats were divided into four groups. Three pairs of bipolar silver electrodes were chronically implanted in the antrum, duodenum and jejunum. Three groups of Uhem were ligatecl around the upper part of common bile duct （CBD）. The experiments were performed in consdous and fasting state. The gastrointestinal myoelectrical activity was recorded. Ursodeoxycholic acid （UDCA） and saline were then perfused into stomachs of two groups with CBD obstruction and the effects of them on the MMC were observed. RESULTS： A typical pattern of MMC was observed in normal fasting rats. MMC of antral and duodenal origin disappeared temporarily in earlier stage of CBD obstruction. While MMC of jejunum origin appeared. increased MMC cycle duration was seen after 4 d in rats with CBD obstruction. The MMC after CBD obstruction was characterized by an increased duration of phase Ⅱ-like activity and decreased duration of phase Ⅰ ＆ Ⅲ activity. Perfusion into stomachs with UDCA resulted in a shorter MMC cycle duration and a longer duration of phase III of duodenal origin compared to the normal group. CONCLUSION： Entero-hepatic bile add drculation initiates inter-digestive MMC of duodenal origin.

关键词： Migrating myoelectrical complex Entero-hepatic Bile acid circulation Ursodeoxycholic acid Common bile duct obstruction

Rituximab or plasmapheresis for prevention of recurrent focal segmental glomerulosclerosis after kidney transplantation:A systematic review and meta-analysis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Transplantation 2021年第7期11卷 303-319页

作者： Boonphiphop Boonpheng Panupong Hansrivijit Charat Thongprayoon Shennen A Mao Pradeep K Vaitla Tarun Bathini Avishek Choudhury Wisit Kaewput Michael A Mao Wisit Cheungpasitporn Division of Nephrology David Geffen School of MedicineUniversity of CaliforniaLos AngelesCA 90095United States Department of internal medicine UPMC PinnacleHarrisburgPA 17104United States Department of medicine Mayo ClinicRochesterMN 55905United States Division of Transplant Surgery Mayo ClinicJacksonvilleFL 32224United States Division of Nephrology Department of Internal MedicineUniversity of Mississippi Medical CenterJacksonMS 39216United States Department of internal medicine University of ArizonaTucsonAZ 85721United States School of Systems and Enterprises Stevens Institute of TechnologyHobokenNJ 07030United States Department of Military and Community medicine Phramongkutklao College of MedicineBangkok 10400Thailand Division of Nephrology and Hypertension Mayo ClinicJacksonvilleFL 32224United States Division of Nephrology and Hypertension Department of MedicineMayo ClinicRochesterMN 55905United States

BACKGROUND Focal segmental glomerulosclerosis(FSGS)is one of the most common glomerular diseases leading to renal *** has a high risk of recurrence after kidney *** of recurrent FSGS using rituximab and/or plasmapheresis has been evaluated in multiple small studies with conflicting *** To assess the risk of recurrence of FSGS after transplantation using prophylactic rituximab with or without plasmapheresis,and plasmapheresis alone compared to the standard treatment group without preventive *** This meta-analysis and systematic review were performed by first conducting a literature search of the MEDLINE,EMBASE,and Cochrane databases,from inception through March 2021;search terms included‘FSGS,’’steroid-resistant nephrotic syndrome’,‘rituximab,’and‘plasmapheresis,’.We identified studies that assessed the risk of post-transplant FSGS after use of rituximab with or without plasmapheresis,or plasmapheresis *** criteria were:Original,published,randomized controlled trials or cohort studies(either prospective or retrospective),case-control,or cross-sectional studies;inclusion of odds ratio,relative risk,and standardized incidence ratio with 95%confidence intervals(CI),or sufficient raw data to calculate these ratios;and subjects without interventions(controls)being used as comparators in cohort and cross-sectional *** estimates from individual studies were extracted and combined using a random effects *** Eleven studies,with a total of 399 kidney transplant recipients with FSGS,evaluated the use of rituximab with or without plasmapheresis;thirteen studies,with a total of 571 kidney transplant recipients with FSGS,evaluated plasmapheresis ***-transplant FSGS recurred relatively *** was no significant difference in recurrence between the group that received rituximab(with or without plasmapheresis)and the standard treatment group,with a pooled risk ratio of 0.82(95%CI:0.47-1.4

关键词： Focal segmental glomerulosclerosis Kidney transplantation Meta-analysis Plasmapheresis Transplantation Systematic review

Precipitating factors leading to decompensation of chronic heart failure in the elderly patient in South-American community hospital

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Geriatric Cardiology 2011年第1期8卷 12-14页

作者： Alejandro Diaz Cleto Ciocchini Mariano Esperatti Alberto Becerra Sabrina Mainardi Alejandro Farah Department of Cardiology Hospital Privado de Comunidad Cordoba 4545 Mar del Plata 7600 Argentina Department of internal medicine Hospital Privado de Comunidad Cordoba 4545 Mar del Plata 7600 Argentina

Background Exacerbations of heart failure appear frequently associated with precipitating factors not directly related to the evolution of cardiac disease. There still a paucity of data on the proportional distribution of precipitating factors specifically in elderly patients. The aim of this study was to examine prospectively the precipitating factors leading to hospitalization in elderly patients with heart failure in our community hospital. Methods We evaluate elderly patients who need admissions for decompensate heart failure. All patients were reviewed daily by the study investigators at the first 24 h and closely followed-up. Decompensation was defined as the worsening in clinical NYHA class associated with the need for an increase in medical treatment （at minimum intravenously diuretics）. Results We included 102 patients （mean age 79 ± 12 years）. Precipitating factors were identified in 88.5%. The decompensation was sudden in 35% of the cases. Noncompliance with diet was identified in 52% of the patients, lack of adherence to the prescribed medications amounted to 30%. Others precipitating factors were infections （29%）, arrhythmias （25%）, acute coronary ischemia （22%）, and uncontrolled hypertension （15%）, miscellaneous causes were detected in 18% of the cases （progression of renal disease 60%, anemia 30% and iatrogenic factors 10%）. Concomitant cause was not recognizable in 11.5%. Conclusions Large proportion heart failure hospitalizations are associated with preventable precipitating factors. Knowledge of potential precipitating factors may help to optimize treatment and provide guidance for patients with heart failure. The presence of potential precipitating factors should be routinely evaluated in patients presenting chronic heart failure.

关键词： heart failure exacerbation elderly patient

The transcription factor PU.1 promotes alternative macrophage polarization and asthmatic airway inflammation

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

分子细胞生物学报:英文版 2015年第6期7卷 557-567页

作者： Feng Qian Jing Deng Yong Gyu Lee Jimmy Zhu Manjula Karpurapu Sangwoon Chung Jun-Nian Zheng Lei Xiao Gye Young Park John W.Christman School of Pharmacy Engineering Research Center of Cell&Therapeutic AntibodyMinistry of EducationShanghai Jiao Tong UniversityShanghaiChina Department of internal medicine Section of PulmonaryAllergyCritical Careand Sleep MedicineThe Ohio State UniversityColumbusUSA Department of Physiology and Biophysics College of MedicineUniversity of Illinois at ChicagoChicagoUSA Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy Cancer InstituteXuzhou Medical CollegeXuzhouChina Department of medicine Section of PulmonaryCritical Careand Sleep MedicineUniversity of Illinois at ChicagoChicagoUSA

The transcription factor PU.1 is involved in regulation of macrophage differentiation and ***,the role of PU.1 in alternatively activated macrophage(AAM)and asthmatic inflammation has yet been *** we report that PU.1 serves as a critical regulator of AAM polarization and promotes the pathological progress of asthmatic airway *** response to the challenge of DRA(dust mite,ragweed,and Aspergillus)allergens,conditional PU.1-deficient(PU/ER(T)^(+/-))mice displayed attenuated allergic airway inflammation,including decreased alveolar eosinophil infiltration and reduced production of IgE,which were associated with decreased mucous glands and goblet cell *** reduced asthmatic inflammation in PU/ER(T)^(+/-) mice was restored by adoptive transfer of IL-4-induced wild-type(WT)***,after treating PU/ER(T)^(+/-) mice with tamoxifen to rescue PU.1 function,the allergic asthmatic inflammation was significantly *** vitro studies demonstrate that treatment of PU.1-deficient macrophages with IL-4 attenuated the expression of chitinase 3-like 3(Ym-1)and resistin-like molecule alpha 1(Fizz-1),two specific markers of AAM *** addition,PU.1 expression in macrophages was inducible in response to IL-4 challenge,whichwas associated with phosphorylation of signal transducer and activator of transcription 6(STAT6).Furthermore,DRAchallenge in sensitized mice almost abrogated gene expression of Ym-1 and Fizz-1 in lung tissues of PU/ER(T)^(+/-) mice compared with WT *** data,all together,indicate that PU.1 plays a critical role in AAM polarization and asthmatic inflammation.

关键词： PU.1 alternatively activated macrophage asthmatic inflammation Th2 IL-4

Sprayable nanomicelle hydrogels and inflammatory bowel disease patient cell chips for development of intestinal lesion-specific therapy

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Bioactive Materials 2022年第12期7卷 433-445页

作者： Hyo-Jin Yoon Songhyun Lee Tae Young Kim Seung Eun Yu Hye-Seon Kim Young Shin Chung Seyong Chung Suji Park Yong Cheol Shin Eun Kyung Wang Jihye Noh Hyun Jung Kim Cheol Ryong Ku Hong Koh Chang-Soo Kim Joon-Sang Park Young Min Shin Hak-Joon Sung Department of Medical Engineering Yonsei University College of MedicineSeoul03722Republic of Korea School of Electrical and Electronic Engineering Yonsei UniversitySeoul03722Republic of Korea Department of Obstetrics and Gynecology Institution of Women’s Life Medical ScienceSeverance HospitalYonsei University College of MedicineSeoul03722Republic of Korea Department of Biomedical Engineering The University of Texas at AustinAustinTX78712USA Department of internal medicine EndocrinologyInstitute of Endocrine ResearchYonsei University College of MedicineSeoul03722Republic of Korea Department of Pediatrics GastroenterologySeverance HospitalYonsei University College of MedicineSeoul03722Republic of Korea Department of Computer Engineering Hongik UniversitySeoul04066Republic of Korea Institute of Tissue Regeneration Engineering(ITREN) Dankook UniversityCheonan31116Republic of Korea Numais Co. Ltd.Korea Seoul 04799Republic of Korea

All-in-one treatments represent a paradigm shift in future *** example,inflammatory bowel disease(IBD)is mainly diagnosed by endoscopy,which could be applied for not only on-site monitoring but also the intestinal lesion-targeted spray of injectable ***,molecular conjugation to the hydrogels would program both lesion-specific adhesion and drug-free *** study validated this concept of all-in-one treatment by first utilizing a well-known injectable hydrogel that underwent efficient solution-to-gel transition and nanomicelle formation as a translatable *** properties enabled spraying of the hydrogel onto the intestinal walls during ***,peptide conjugation to the hydrogel guided endoscopic monitoring of IBD progress upon adhesive gelation with subsequent moisturization of inflammatory lesions,specifically by *** peptide was designed to mimic the major component that mediates intestinal interaction with Bacillus subtilis flagellin during IBD ***,the peptide-guided efficient adhesion of the hydrogel nanomicelles onto Toll-like receptor 5(TLR5)as the main target of flagellin binding and *** peptide binding potently suppressed inflammatory signaling without drug loading,where TLR5 and Notch-1 operated collaboratively through downstream actions of tumor necrosis *** results were produced using a human colorectal cell line,clinical IBD patient cells,gut-on-a-chip,a mouse IBD model,and pig experiments to validate the translational utility.

关键词： Nanomicelle Injectable hydrogel Peptide display Theranostic All-in-one treatment Inflammatory bowel disease

Distributions of Sasang constitutions and six syndromes in patients with functional dyspepsia and healthy subjects

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Traditional Chinese medicine 2013年第5期33卷 626-629页

作者： Junghyo Cho Yochan Ahn Dongsoo Lee Changgue Son Liver and Immunology Research Center Daejeon Oriental Hospital of Daejeon University Department of Health Service Management Daejeon University Department of internal medicine Daejeon St. Mary's Hospita The Catholic University of Korea

OBJECTIVE:To investigated the characteristics of patients with functional dyspepsia(FD)in terms of Sasang constitutional ***:A total of 116 patients with FD were recruited based on diagnosis by gastroscopy and symptomatic *** distributions of Sasang constitutions and six syndromes in terms of TKM theory in the patients was compared with those from 1423 healthy ***:The distribution of Sasang constitutions for the patients with FD significantly differed from that for healthy subjects,especially among women;36.7%vs 45.6%for Taeumin,28.9%vs 33.9%for Soumin,and 34.4%vs 20.4%for *** results assumed a high prevalence in Soyangin women(around 1.7 folds),and Soumin(45.2%),inparticular,had a high prevalence of"deficiency and coldness of spleen and stomach"compared with Taeumin(14.9%)and Soyangin types(15.7%).CONCLUSION:This study identified a trend for the frequency of FD and the Sasang *** findings may provide new ideas for the study of prevention and management of FD.

关键词： Dyspepsia Sasang constitution Syndrome differentiation medicine Chinese traditional medicine Korean traditional

Identify multiple myeloma stem cells: Utopia?

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

World Journal of Stem Cells 2015年第1期7卷 84-95页

作者： Ilaria Saltarella Aurelia Lamanuzzi Antonia Reale Angelo Vacca Roberto Ria Department of Biomedical Sciences and Human Oncology Section of Internal Medicine "G. Baccelli" University of Bari "Aldo Moro" Medical School Policlinico I-70124 Bari Italy

Multiple myeloma(MM) is a hematologic malignancy of monoclonal plasma cells which remains incurable despite recent advances in therapies. The presence of cancer stem cells(CSCs) has been demonstrated in many solid and hematologic tumors, so the idea of CSCs has been proposed for MM, even if MM CSCs have not been define yet. The existence of myeloma CSCs with clonotypic B and clonotypic non B cells was postulated by many groups. This review aims to focus on these distinct clonotypic subpopulations and on their ability to develop and sustain MM. The bone marrow microenvironment provides to MM CSCs self-renewal, survival and drug resistance thanks to the presence of normal and cancer stem cell niches. The niches and CSCs interact each other through adhesion molecules and the interplay between ligands and receptors activate stemness signaling(Hedgehog, Wnt and Notch pathways). MM CSCs are also supposed to be responsible for drug resistance that happens in three steps from the initial cancer cell homing microenvironment-mediated to development of microenvironment-independent drug resistance. In this review, we will underline all these aspects of MM CSCs.

关键词： Bone marrow microenvironment Cancerstem cells Multiple myeloma Stem cells niche Stemness

Nicotinic acid: Do we know how it works after 55 years of clinical experience?

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Pharmacology 2012年第3期1卷 50-54页

作者： Anastazia Kei Moses S Elisaf Department of internal medicine School of Medicine University of Ioannina 45110 Ioannina Greece

Nicotinic acid （NA） comprises the oldest hypolipidemic drug, in use since 1955. Despite its established broad spectrum effect on lipid profle and the associated re-duction in cardiovascular morbidity and mortality, the mechanisms by which NA achieves its benefcial effects remain elusive. Regarding the NA-associated reduction in triglyceride and low density lipoprotein cholesterol levels, data are controversial. The prevailing view which suggested that NA inhibits lipolysis and decreases free fatty acid （FFA） release both via activation of adipose tissue G-protein receptor-109A （GPR109A） and via inhibition of hepatic triglyceride synthesis is currently debated by the observation that the initially decreased FFA levels rebound during long-term NA treatment even though the benefcial NA effects on lipid metabo-lism are preserved, while other mechanisms involving modulation of transcription and translation pathways are emerging. In addition, NA has been demonstrated to affect high density lipoprotein （HDL） particles remod-eling in a number of ways, including reducing choles-terol ester transfer protein levels and activity, increas-ing apolipoprotein A-I levels, eliminating HDL hepatic uptake, increasing cholesterol efflux via ATP-binding cassette A1, inhibiting hepatic lipase, thereby overall in-creasing the plasma residence time of HDL and apoA-I with retention of cholesterol esters in HDL. Focus of this article is to present the mechanisms by which NA exerts its broad spectrum hypolipidemic actions.

关键词： Dyslipidemia Nicotinic acid Niacin Mechanisms GPR109A Free fatty acids

Toward Evidence-Based Chinese medicine：Status Quo,Opportunities and Challenges

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Journal of Integrative medicine 2018年第3期24卷 163-170页

作者： CHEN Yao-long ZHAO Chen ZHANG Li LI Bo WU Chuan-hong MU Wei WANG Jia-ying YANG Ke-hu LI You-ping CHEN Chiehfeng WANG Yong-yan WANG Chen BIAN Zhao-xiang SHANG Hong-cai Key Laboratory of Chinese internal medicine of Ministry of Education Dongzhimen Hospital Beijing University of ChineseMedicine Beijing 100007 China Evidence Based medicine Center School of Basic Medical Sciences Lanzhou UniversityLanzhou 730000 China Key Laboratory of Evidence Based medicine and Knowledge Translation of Gansu Province Lanzhou 730000 China Chinese GRADE Center Lanzhou 730000China China School of Chinese medicine Hong Kong Baptist University Hong Kong SAR 999077 China Departmentof Clinical Pharmacology Second Affiliated Hospital of Tianjin University of Traditional Chinese MedicineTianjin 300193China Department of gastroenterology Beijing Hospital of Traditional Chinese Medicine Capital Medical University Beijing 100091 China State Key Laboratory of Quality Researchin Chinese medicine Institute of Chinese Medical SciencesUniversity of Macao Macao 999078 China Departmentof Acupuncture and Moxibustion Wuxi People's HospitalJiangsu 214023 China Chinese Cochrane Centre West China Hospital Sichuan University Chengdu 610041 China Division of Plastic Surgery Department of Surgery Wan Fang Hospital Taipei Medical University Taipei 106 China Instituteof Basic Research in Clinical medicine China Academy of Chinese Medical Sciences Beijing 100700 China Department of Respiratory and Critical Care medicine China-Japan Friendship Hospital. Beiiina 100029. China

How to test the treatments of Chinese medicine（CM） and make them more widely accepted by practitioners of Western medicine and the international healthcare community is a major concern for practitioners and researchers of *** centuries,various approaches have been used to identify and measure the efficacy and safety of ***,the high-quality evidence related to CM that produced in China is still *** the recent years,evidence-based medicine（EBM） has been increasingly applied to CM,strengthening its theoretical *** paper reviews the past and present state of CM,analyzes the status quo,challenges and opportunities of basic research,clinical trials,systematic reviews,clinical practice guidelines and clinical pathways and evidence-based education developed or conducted in China,pointing out how EBM can help to make CM more widely used and recognized worldwide.

关键词： evidence-based medicine Chinese medicine randomized controlled trial systematic review clinical practice guidelines

Malignant peritoneal mesothelioma with massive ascites as the first symptom:A case report

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2022年第28期10卷 10317-10325页

作者： Xi Huang Yu Hong Si-Ya Xie Hui-Li Liao Hao-Ming Huang Jian-Hong Liu Wen-Jie Long Department of Geriatrics The First Affiliated Hospital of Guangzhou University of Chinese MedicineGuangzhou 510006Guangdong ProvinceChina Department of Chinese internal medicine The First Clinical Medical CollegeGuangzhou University of Chinese MedicineGuangzhou 510006Guangdong ProvinceChina Department of Geriatrics The First Clinical Medical CollegeGuangzhou University of Chinese MedicineGuangzhou 510006Guangdong ProvinceChina Department of Emergency The First Affiliated Hospital of Guangzhou University of Chinese MedicineGuangzhou 510006Guangdong ProvinceChina

BACKGROUND Malignant peritoneal mesothelioma(MPM) is an extremely rare tumor with nonspecific clinical manifestations,which is extremely difficult to ***,we reported a case of MPM in the abdominal cavity with massive shortterm ascites as the first *** SUMMARY A 65-year-old woman presented to the hospital with abdominal pain,distention,and shortness of breath that persisted for 15 *** serum CA-125 level was 1075 U/m *** abdominal computed tomography showed massive ascites and no obvious tumor *** pathological examination of the ascitic fluid showed numerous heterotypic cells with some papillary *** immunohistochemistry and fluorescence in situ hybridization showed the deletion of CDX2(-),WT-1(-),Ki-67(about 10% +),CEA(-),Glut-1(+++),desmin(-),PD-L1(-),and CDKN2A(P16).The final diagnosis was *** patient refused tumor cytoreductive surgery and received two cycles of cisplatin plus pemetrexed bidirectional *** the second cycle,she received an additional cycle of hyperthermic intraperitoneal chemotherapy and immune checkpoint inhibitor therapy due to massive recalcitrant *** died of disease progression 2 mo after *** In case of massive unexplained ascites,the possibility of MPM should not be excluded to avoid misdiagnosis and delay in treatment.

关键词： Malignant peritoneal mesothelioma Ascites Immunohistochemistry Chemotherapy Immunotherapy Case report